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Aducanumab for Alzheimer’s disease: The never- ending story 
that nurses should know
In October 2019, the American pharmaceutical company Biogen 
stated intention to apply to the US Food and Drug Administration 
(FDA) for the candidate drug aducanumab to be licenced as a ther-
apeutic agent for the treatment of Alzheimer's disease (AD). If 
approved, aducanumab would become the first new medication li-
cenced specifically for the treatment of AD in the past decade; and 
approval in the US may be a precipitant for approval elsewhere.
Predictably, the potential advent of a new drug for AD has re-
sulted in considerable excitement amongst the general population, 
healthcare professionals and AD charities alike (Alzheimer’s Research 
UK, 2019). This enthusiasm is understandable as aducanumab has 
been posited as a medication that can reduce brain amyloid accumu-
lations and reduce clinical decline seen in AD (Biogen, 2019a; Wang 
& Holtzman, 2020), which is currently viewed as a progressive and 
irreversible neurodegenerative condition with cerebral atrophy, cog-
nitive decline and a loss of functionality for the individual (Wang & 
Holtzman, 2020).
Currently approved evidence- based pharmacological agents 
for AD include acetylcholinesterase inhibitors, such as donepe-
zil and galantamine, and the glutamatergic antagonist memantine 
(BNF, 2021). An important distinction to make is that presently ap-
proved medications are considered to slow the progression of AD 
whereas aducanumab has been stated to reverse the pathological 
process, and associated clinical decline, by way of clearance of ex-
tracellular amyloid beta plaques observed within AD (Carroll, 2020). 
If aducanumab really can reverse these features and reduce the cog-
nitive decline, this would be a revolutionary treatment.
Whilst on the surface this sounds a very positive advance with 
significant potential, the decision by Biogen to pursue FDA approval 
has raised some concerns (Carroll, 2020). Aducanumab – a high- 
affinity, fully human IgG1 monoclonal antibody – is actually not a 
new drug; it was first produced by Neurimmune and its licence was 
sold to Biogen in 2007 (Neurimmune, 2020). There have been sev-
eral earlier studies exploring aducanumab within the treatment of 
AD which failed to demonstrate efficacy when compared to placebo. 
This apparent lack of response to aducanumab within clinical trials 
had led to Biogen's own phase three trials being discontinued in early 
2019 (Biogen, 2019a). Despite discontinuing the trials, Biogen un-
dertook a retrospective data trawl which has appeared to uncover 
incorrect analysis earlier in the study, leading Biogen to claim that 
the original trial dose was too small and that one of the two- phase 
three clinical trials [the EMERGE trial] actually did reduce clinical de-
cline in patients with early AD (Biogen, 2019b). This statement of 
success appeared conflicted with an earlier disclosure highlighting 
that the trial did not need the pre- specified end point, so confusion 
abounds. This new analysis of the data was reported to have ob-
served a “statistically significant reduction in clinical decline in early AD 
patients,” and it has been claimed that greater exposure to high dose 
aducanumab was the primary driver for the apparent positive results 
(Biogen, 2019a).
Following Biogen's announcement to seek FDA approval which 
was declared without full disclosure of supporting data at the time- 
independent analyses was undertaken following public presentation 
of the data during on 5th December 2020. These data have split 
opinion with regard to the potential efficacy for AD with proto-
col amendments, initiated mid- study in 2017, proving problematic 
for many reviewing the data. The conflict as to whether the data 
presented were a true reflection of an objective and transparent 
trial remains palpable. Indeed, the UK Alzheimer’s Society (2019; 
Alzheimer’s Research UK, 2019) state it is not possible to deter-
mine whether aducanumab is effective, yet the US Alzheimer's 
Association are currently strongly advocating for approval by the 
FDA (Alzheimer’s Association, 2020); even stating that a further 
delay to undertake additional clarifying trials would not be accept-
able. AD charities have an influence about the hopes of people living 
with dementia, their carers and many healthcare professionals; and 
it could be argued that advocating for FDA approval may be pro-
viding a higher level of optimism than is perhaps realistic. Given the 
important role of many charitable organisations, it is of paramount 
importance that the public are aware of the conflicting messages 
emanating from what are two of the most well- known AD charities, 
to permit objective discussions based on the evidence.
Currently, we are still awaiting a decision by FDA as to whether 
approve aducanumab for clinical practice. This decision was due 
to be made in March 2021 but has now been delayed until 7 June 
2021. This delay is following an FDA request for additional data from 
Biogen, which has been provided. This should be viewed in the con-
text of an FDA advisory committee which met in November 2020 
and raised significant concerns questioning the effectiveness of 
aducanumab. The outcome of this advisory committee appeared to 
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suggest that the application would be rejected, with the panel voting 
against approving aducanumab. Despite this, it is noteworthy that 
the FDA is not obliged to follow the committee's advice (Bowman 
Rogers, 2020). Interestingly, the peaks and troughs of optimism 
about this candidate drug have been reflected in Biogen's stock mar-
ket status.
On a wider perspective, few could argue that it is not exciting 
that there is renewed scientific and pharmaceutical interest within 
the area of AD, something which appears to have reduced over re-
cent years, perhaps due to the complexity of AD pathophysiology. 
Aducanumab may indeed turn out to be the first medication which 
removes extracellular accumulations of amyloid beta, but others 
may follow. These include both donanemab and gantenerumab, 
amongst others, and there is renewed life within these candidate 
drugs following on from the apparent positive findings related to 
aducanumab (Adams, 2021). However, the inescapable reality is that 
AD pathophysiology is highly complex. This is demonstrated fur-
ther still when considering that the accumulation of amyloid beta, 
the target of aducanumab and other candidate drugs, continues to 
be poorly associated with levels of cognition and that clearance of 
amyloid does not appear to be commensurate with improvement to 
cognition (Ackley et al., 2021).
So, what might this mean for mental health care and nursing prac-
tice in 2021 and beyond? Well, much of this depends upon the FDA 
and their decision about approval; along with the decisions made by 
further regulatory organisations worldwide. At best, a further medi-
cation may be available, although as it would be based upon the cur-
rent data set it may be prudent to scrutinise the data and to ask just 
how beneficial this may be. There are further considerations also – at 
a time when many economies have regressed because of the SARS- 
CoV- 2 pandemic – of where and how future health spending is un-
dertaken is critically important. Our current psychopharmacological 
interventions remain affordable options with a good evidence base 
for efficacy in mild- moderate AD. These medications augmented 
with comprehensive, person- centred psychosocial interventions and 
skilled nursing input must remain at the centre of therapeutic inter-
ventions. The approval of a costly new medication with potentially 
dubious effectiveness could jeopardise care packages which are evi-
denced to increase the quality of life for those with a diagnosis of AD.
It could be argued that this situation may illustrate a broader 
issue of how pharmaceutical companies can influence treatment 
hopes. Further, this circumstance also demonstrates how the recom-
mendations of respected charities (which may well be the primary 
source of health literacy information for the general public), when 
based on preliminary findings that are not peer- reviewed or subject 
to the usual checks and balances of the scientific publishing process, 
could have an adverse effect on the quality of life for those living 
with a diagnosis of dementia and their families.
In summary, the availability of new medications that can reduce 
accumulations of amyloid beta in AD is an exciting prospect. This po-
tential treatment development is of great interest to all stakeholders 
and is likely to become a topic of discussion within clinical meetings 
with nurses that work with people who live with mild- moderate AD 
and their carers. However, nurses need to know that clearance of am-
yloid does not necessary improve cognition in AD, that the evidence 
of effectiveness of aducanumab remains unclear (despite strong 
support from the US Alzheimer's Association) and that currently the 
best evidence- based treatment approaches involve person- centred 
psychosocial interventions combined with acetylcholinesterase in-
hibitors and memantine.
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